Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

Decoy Therapeutics Inc.

Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.
New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.
Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.
Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Decoy Therapeutics Inc.: Amended Certificate of Incorporation to effect a 1-for-12 reverse stock split of common stock (effective 2026-03-06).

Change: charter amendment
Effective: 2026-03-06

Exact text from the filing

On March 5, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.

View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.